In vivo interactions of apoA-II, apoA-I, and hepatic lipase contributing to HDL structure and antiatherogenic functions

Mice models including apoA-II transgenic, combined apoA-II transgenic/hepatic lipase knockout (HLko), combined apoA-I/apoA-II transgenic, and nontransgenic mice

Genetic modification (overexpression of apoA-I, apoA-II, and/or hepatic lipase knockout)

Nontransgenic mice or single transgenic mice

HDL size, hepatic lipase hydrolysis, atherosclerotic lesion formation, and anti-inflammatory properties of HDLsurrogate